Erytech Pharma’s (ERYP) Buy Rating Reaffirmed at Cowen
Cowen reiterated their buy rating on shares of Erytech Pharma (NASDAQ:ERYP) in a report released on Sunday, AnalystRatings.com reports.
Several other research firms have also recently weighed in on ERYP. JMP Securities reissued a market outperform rating and issued a $13.00 price objective on shares of Erytech Pharma in a research report on Thursday, September 5th. Zacks Investment Research cut Erytech Pharma from a hold rating to a sell rating in a research report on Thursday, September 19th. Finally, ValuEngine raised Erytech Pharma from a hold rating to a buy rating in a research report on Thursday, August 15th.
Shares of ERYP traded up $0.04 during mid-day trading on Friday, hitting $5.20. The company’s stock had a trading volume of 300 shares, compared to its average volume of 921. Erytech Pharma has a one year low of $3.95 and a one year high of $10.65. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.90 and a current ratio of 5.91. The firm has a market capitalization of $92.56 million, a PE ratio of 2.13 and a beta of 1.48. The stock’s 50-day moving average is $4.47 and its two-hundred day moving average is $5.94.
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
See Also: Why do corrections happen?
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.